We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb’s (BMS’) recent decision to stop marketing its antidepressant Serzone (nefazodone HCl) will give generics 100 percent of the market of the former top-selling product — a situation that presents mixed opportunities for generic firms, according to industry observers.
The FTC has given its blessing to a deal between Teva Pharmaceutical and Bristol-Myers Squibb (BMS) that lets Teva launch an authorized version of BMS’ cancer drug Paraplatin (carboplatin) nearly four months before other generic firms.
In a policy shift that could allow generic firms to sell AIDS drugs that are still under patent, U.S. health officials are easing the way for brand and generic drugmakers to submit applications for fixed-dose combination (FDC) products to treat HIV in poor countries.
Generic firm Andrx has given up its 180-day exclusive market rights for a 150-mg strength version of GlaxoSmithKline’s (GSK’s) smoking cessation drug Zyban (bupropion HCl), a move that allows other generic firms to start marketing the product.
Under legal fire from a wide-ranging assortment of litigants, Abbott Laboratories defended its 400 percent price hike on the AIDS drug Norvir, saying the increase reflects the true market value of the product, which remains the lowest-priced drug at its dose in the protease inhibitor class.
The California Assembly passed bills this week that could on the one hand improve drugmakers’ negotiating position with pharmaceutical benefit managers (PBMs) and on the other hand add new momentum to the effort to reimport prescription drugs from Canada.
Unlike the boom-bust cycle in the biotech industry four years ago, current growth in the market may be sustainable based on a more rational view of individual biotech firms and an increasing awareness of the products’ potential to yield innovative healthcare, say industry analysts in a new study.
The prices of common brand drugs used by seniors have increased by more than three times the rate of inflation in recent years, according to two new studies.
Despite losing patent protection on many key drugs, brand firms may still have an advantage over generic rivals for products used to treat severe illnesses, according to a new survey on consumer attitudes toward generic drugs.
After a sharp market downturn in the previous two years, the biotech industry started to surge in 2003, driven in part by a critical mass of biological drugs on the market and many experimental products on the verge of gaining FDA approval, a new study finds.